Skip to main content
. 2009 Oct 18;24(Suppl 2):383–388. doi: 10.1007/s11606-009-1037-2

Table 2.

Fracture and Cardiovascular Event Rates in Aromatase Inhibitor Versus Tamoxifen Studies

Study Drug N Duration (months) Fractures Cardiovascular events
% (N) % (N)
ATAC64 Anastrozole 3125 100 16.6 (521)* 1.9 (60)
Tamoxifen 3116 12.0 (377) 1.9 (61)
BIG 1–9843 Letrozole 2448 40 8.0 (196)* 5.7 (140)
Tamoxifen 2447 5.4 (132) 5.2 (127)
IES65 Exemestane 2320 55 4.3 (100)* 16.4 (382)
Tamoxifen 2338 3.1 (73) 15.0 (350)

* P< 0.05.

Arimidex, Tamoxifen Alone or in Combination trial, Breast International Group 1-98 trial, Intergroup Exemestane Study.